{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:56:48Z","timestamp":1790377008089,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04365-4","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:05:13Z","timestamp":1778493913000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Milan","family":"Radovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Solzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongseok","family":"Tae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Maney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hamrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George W.","family":"Sledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet S.","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen V.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Spetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"2","key":"4365_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/imm.12459","volume":"145","author":"VA Zavala","year":"2015","unstructured":"Zavala VA, Kalergis AM (2015) New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 145(2):182\u2013201","journal-title":"Immunology"},{"issue":"26","key":"4365_CR2","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454","journal-title":"N Engl J Med"},{"issue":"6","key":"4365_CR3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1093\/annonc\/mdx076","volume":"28","author":"SP Kang","year":"2017","unstructured":"Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB et al (2017) Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol 28(6):1388\u20131398","journal-title":"Ann Oncol"},{"issue":"8","key":"4365_CR4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908\u2013918","journal-title":"Lancet Oncol"},{"issue":"19","key":"4365_CR5","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823\u20131833","journal-title":"N Engl J Med"},{"issue":"14","key":"4365_CR6","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1200\/JCO.19.02446","volume":"38","author":"RS Herbst","year":"2020","unstructured":"Herbst RS, Garon EB, Kim D-W, Cho BC, Perez-Gracia JL, Han J-Y et al (2020) Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1\u2012positive, advanced non\u2012small-cell lung cancer in the KEYNOTE-010 study. J Clin Oncol 38(14):1580\u20131590","journal-title":"J Clin Oncol"},{"issue":"6","key":"4365_CR7","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","volume":"30","author":"Y Fradet","year":"2019","unstructured":"Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970\u2013976","journal-title":"Ann Oncol"},{"issue":"15","key":"4365_CR8","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","volume":"390","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN et al (2024) Overall survival with adjuvant pembrolizumab in renal-cell carcinoma. N Engl J Med 390(15):1359\u20131371","journal-title":"N Engl J Med"},{"issue":"6230","key":"4365_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Chan TA (2015) Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science 348(6230):124\u2013128","journal-title":"Science"},{"issue":"23","key":"4365_CR10","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","volume":"371","author":"A Snyder","year":"2014","unstructured":"Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189\u20132199","journal-title":"N Engl J Med"},{"issue":"12","key":"4365_CR11","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.18.01042","volume":"37","author":"N Ready","year":"2019","unstructured":"Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF et al (2019) First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 37(12):992\u20131000","journal-title":"J Clin Oncol"},{"issue":"10031","key":"4365_CR12","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387(10031):1909\u20131920","journal-title":"Lancet"},{"issue":"10064","key":"4365_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389(10064):67\u201376","journal-title":"Lancet"},{"key":"4365_CR14","unstructured":"KEYTRUDA\u00ae (pembrolizumab). HIGHLIGHTS OF PRESCRIBING INFORMATION. Merck Sharp & Dohme LLC. 2025. https:\/\/www.merck.com\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf. Accessed Sept 3, 2025. ."},{"key":"4365_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30445-9","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K et al (2020) Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(20)30445-9","journal-title":"Lancet Oncol"},{"key":"4365_CR16","unstructured":"United States Food and Drug Administration. FDA approves pembrolizumab for adults and children with TMB-H solid tumors 2020 [Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors."},{"key":"4365_CR17","doi-asserted-by":"publisher","first-page":"v475","DOI":"10.1093\/annonc\/mdz253.018","volume":"30","author":"A Marabelle","year":"2019","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K et al (2019) Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158. Ann Oncol 30:v475-532","journal-title":"Ann Oncol"},{"issue":"3","key":"4365_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K et al (2022) Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE 17(3):e0264138","journal-title":"PLoS ONE"},{"issue":"3","key":"4365_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A et al (2015) Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17(3):251\u2013264","journal-title":"J Mol Diagn"},{"key":"4365_CR20","doi-asserted-by":"publisher","first-page":"642","DOI":"10.18632\/oncotarget.28761","volume":"16","author":"V Domenyuk","year":"2025","unstructured":"Domenyuk V, Benson K, Carter P, Magee D, Zhang J, Bhardwaj N et al (2025) Clinical and analytical validation of MI Cancer Seek\u00ae, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay. Oncotarget 16:642\u2013659","journal-title":"Oncotarget"},{"key":"4365_CR21","unstructured":"US Food and Drug Administration. FDA grants approval to atezolizumab for alveolar soft part sarcoma 2022 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-approval-atezolizumab-alveolar-soft-part-sarcoma."},{"key":"4365_CR22","unstructured":"United States Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue\/site agnostic indication 2017 [Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication."},{"key":"4365_CR23","doi-asserted-by":"crossref","unstructured":"Sung MT, Wang YH, Li CF. Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. Int J Mol Sci. 2022;23(9).","DOI":"10.3390\/ijms23095097"},{"issue":"4","key":"4365_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/ijc.31878","volume":"144","author":"I Buchhalter","year":"2019","unstructured":"Buchhalter I, Rempel E, Endris V, Allg\u00e4uer M, Neumann O, Volckmar AL et al (2019) Size matters: dissecting key parameters for panel-based tumor mutational burden analysis. Int J Cancer 144(4):848\u2013858","journal-title":"Int J Cancer"},{"issue":"9","key":"4365_CR25","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/annonc\/mdz205","volume":"30","author":"J Budczies","year":"2019","unstructured":"Budczies J, Allg\u00e4uer M, Litchfield K, Rempel E, Christopoulos P, Kazdal D et al (2019) Optimizing panel-based tumor mutational burden (TMB) measurement. Ann Oncol 30(9):1496\u20131506","journal-title":"Ann Oncol"},{"issue":"6","key":"4365_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.21037\/tlcr.2018.08.14","volume":"7","author":"M Allg\u00e4uer","year":"2018","unstructured":"Allg\u00e4uer M, Budczies J, Christopoulos P, Endris V, Lier A, Rempel E et al (2018) Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians. Transl Lung Cancer Res 7(6):703\u2013715","journal-title":"Transl Lung Cancer Res"},{"issue":"12","key":"4365_CR27","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA (2020) Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov 10(12):1808\u20131825","journal-title":"Cancer Discov"},{"issue":"12","key":"4365_CR28","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.annonc.2021.09.016","volume":"32","author":"DM Vega","year":"2021","unstructured":"Vega DM, Yee LM, McShane LM, Williams PM, Chen L, Vilimas T et al (2021) Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. Ann Oncol 32(12):1626\u20131636","journal-title":"Ann Oncol"},{"issue":"1","key":"4365_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9(1):34","journal-title":"Genome Med"},{"key":"4365_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000147","author":"DM Merino","year":"2020","unstructured":"Merino DM, McShane LM, Fabrizio D, Funari V, Chen SJ, White JR et al (2020) Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the friends of cancer research TMB harmonization project. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000147","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4365_CR31","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1200\/JCO.2017.75.3384","volume":"36","author":"H Rizvi","year":"2018","unstructured":"Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D et al (2018) Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing. J Clin Oncol 36(7):633\u2013641","journal-title":"J Clin Oncol"},{"issue":"1","key":"4365_CR32","first-page":"56","volume":"3","author":"H Fang","year":"2023","unstructured":"Fang H, Bertl J, Zhu X, Lam TC, Wu S, Shih DJH et al (2023) Tumour mutational burden is overestimated by target cancer gene panels. J Natl Cancer Cent 3(1):56\u201364","journal-title":"J Natl Cancer Cent"},{"issue":"7","key":"4365_CR33","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jtho.2020.01.023","volume":"15","author":"A Stenzinger","year":"2020","unstructured":"Stenzinger A, Endris V, Budczies J, Merkelbach-Bruse S, Kazdal D, Dietmaier W et al (2020) Harmonization and standardization of panel-based tumor mutational burden measurement: real-world results and recommendations of the quality in pathology study. J Thorac Oncol 15(7):1177\u20131189","journal-title":"J Thorac Oncol"},{"issue":"6","key":"4365_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jmoldx.2022.01.008","volume":"24","author":"B Wei","year":"2022","unstructured":"Wei B, Kang J, Kibukawa M, Arreaza G, Maguire M, Chen L et al (2022) Evaluation of the trusight oncology 500 assay for routine clinical testing of tumor mutational burden and clinical utility for predicting response to pembrolizumab. J Mol Diagn 24(6):600\u2013608","journal-title":"J Mol Diagn"},{"issue":"10","key":"4365_CR35","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/1535-7163.MCT-20-0161","volume":"19","author":"P Riviere","year":"2020","unstructured":"Riviere P, Goodman AM, Okamura R, Barkauskas DA, Whitchurch TJ, Lee S et al (2020) High tumor mutational burden correlates with longer survival in immunotherapy-na\u00efve patients with diverse cancers. Mol Cancer Ther 19(10):2139\u20132145","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4365_CR36","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1038\/s41467-025-57941-0","volume":"16","author":"GW Sledge Jr","year":"2025","unstructured":"Sledge GW Jr, Yoshino T, Xiu J, Helmstetter A, Ribeiro JR, Klimov S et al (2025) Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals. Nat Commun 16(1):2646","journal-title":"Nat Commun"},{"issue":"1","key":"4365_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4161\/cam.4.1.10884","volume":"4","author":"M Varella-Garcia","year":"2010","unstructured":"Varella-Garcia M (2010) Chromosomal and genomic changes in lung cancer. Cell Adh Migr 4(1):100\u2013106","journal-title":"Cell Adh Migr"},{"issue":"4","key":"4365_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.euus.2005.09.003","volume":"3","author":"JWF Catto","year":"2005","unstructured":"Catto JWF, Hamdy FC (2005) The role of genetic instability in the pathogenesis and progression of urothelial carcinoma. EAU Update Ser 3(4):180\u2013188","journal-title":"EAU Update Ser"},{"key":"4365_CR39","unstructured":"National Comprehensive Cancer Network. Non-Small Cell Lung Cancer (Version 3.2026) 2026 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf."},{"issue":"2","key":"4365_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","volume":"98","author":"YCS Ram\u00f3n","year":"2020","unstructured":"Ram\u00f3n YCS, Ses\u00e9 M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ et al (2020) Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl) 98(2):161\u2013177","journal-title":"J Mol Med (Berl)"},{"issue":"11","key":"4365_CR41","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2019.07.006","volume":"14","author":"D Kazdal","year":"2019","unstructured":"Kazdal D, Endris V, Allg\u00e4uer M, Kriegsmann M, Leichsenring J, Volckmar A-L et al (2019) Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts. J Thorac Oncol 14(11):1935\u20131947","journal-title":"J Thorac Oncol"},{"key":"4365_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2023.100003","volume":"1","author":"S Mishima","year":"2023","unstructured":"Mishima S, Nakamura Y, Tukachinsky H, Taniguchi H, Kadowaki S, Kato K et al (2023) Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. The Journal of Liquid Biopsy 1:100003","journal-title":"The Journal of Liquid Biopsy"},{"issue":"2","key":"4365_CR43","doi-asserted-by":"publisher","first-page":"e010311","DOI":"10.1136\/jitc-2024-010311","volume":"13","author":"DR Gandara","year":"2025","unstructured":"Gandara DR, Agarwal N, Gupta S, Klempner SJ, Andrews MC, Mahipal A et al (2025) Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer 13(2):e010311","journal-title":"J Immunother Cancer"},{"key":"4365_CR44","doi-asserted-by":"publisher","first-page":"1209243","DOI":"10.3389\/fcell.2023.1209243","volume":"11","author":"SF Mo","year":"2023","unstructured":"Mo SF, Cai ZZ, Kuai WH, Li X, Chen YT (2023) Universal cutoff for tumor mutational burden in predicting the efficacy of anti-PD-(L)1 therapy for advanced cancers. Front Cell Dev Biol 11:1209243","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"4365_CR45","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41416-024-02826-0","volume":"131","author":"S Chowdhury","year":"2024","unstructured":"Chowdhury S, Xiu J, Ribeiro JR, Nicolaides T, Zhang J, Korn WM et al (2024) Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors. Br J Cancer 131(8):1328\u20131339","journal-title":"Br J Cancer"},{"key":"4365_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-013186","author":"K Ashouri","year":"2025","unstructured":"Ashouri K, Millstein J, Yang Y, Xiu J, Soni S, Mittal P et al (2025) Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)\/SWOG 80405 and real-world data. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2025-013186","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04365-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T10:05:23Z","timestamp":1778493923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04365-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4365"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04365-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MR, JW, JS, HT, JRR, TM, Bradley H, JH, GWS, DM, and DS are employees of Caris Life Sciences and disclose stock and\/or stock options in the company. MA reports research grants from Pfizer and Incyte; consulting for Bayer, Xoft, Apollomics, Autem therapeutics, GT Medical Technologies, Modifi biosciences, Bugworks, Allovir, EquilliumBio, VBI Vaccines, Servier Pharmaceuticals, Incyte, Recordati, Novocure, and Abbvie; and stock options in Mimivax, MedInnovate Advisors LLC, Trisalus Lifesciences, and LiveAI. SL reports advisory Board \/ consultant role with Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Genentech\/Roche, Gilead, GSK, Guardant Health, Johnson & Johnson, Jazz Pharmaceuticals, Merck, Merus, Natera, Novartis, Nuvalent, OSE Immunotherapeutics, Pfizer, PharmaMar, Regeneron, Revolution Medicines, SystImmune, Takeda, and Yuhan; and research grants (to institution) from Abbvie, Alkermes, AstraZeneca, Avenzo, BioNTech, Bristol-Myers Squibb, Cogent Biosciences, Duality, Ellipses, Genentech, Gilead, Medilink, Merck, Merus, Nuvalent, Nuvation, OSE Immunotherapeutics, Puma, Synthekine, SystImmune. EL reports support and research grants from the American Cancer Society (RSG-22\u2013022-01-CDP) 2022\u20132026 and from the University of Minnesota Clinical Center for the Study of Pancreatic Disease, part of The Chronic Pancreatitis Diabetes Pancreatic Cancer research (CPDPC) consortium funded by the NIDDK (5U01DK126300-03); financial interests in Ryght, Inc.; consultant and advisor for Myer Research, Inc.; paid consultant for Primum; honoraria from Medscape; compensation for scientific review of proposed printed content, Elsevier Publishing and Johns Hopkins Press; Institutional Principal Investigator for clinical trials sponsored by Celgene, Novocure, Ltd, Intima Bioscience, Inc., the National Cancer Institute, and University of Minnesota membership in the Caris Life Sciences Precision Oncology Alliance (no financial compensation). VS reports research funding for clinical trials paid to institution from AbbVie, Agensys, Alfasigma, Altum, Amgen, Bayer, BERG Health, Blueprint Medicine, Boston Biomedical, Boston Pharmaceuticals, D3 Bio, Dragonfly Therapeutics, Exelixis, Fujifilm, GSK, Idera Pharmaceuticals, Incyte, Inhibrix, Eli Lilly\/Loxo Oncology, MedImmune, NanoCarrier, Novartis, PharmaMar, Pfizer, Relay Therapeutics, Roche\/Genentech, Takeda, Turning Point Therapeutics, and Vegenics; consulting\/advisory role (paid to institution) from AbbVie, Astex Pharmaceuticals, AstraZeneca, Bayer, Genmab, Incyte, Lilly\/Loxo Oncology, Novartis, Obsidian Therapeutics, Pfizer, Pheon Therapeutics, Regeneron, Relay Therapeutics, Roche, Endeavor Biomedicines, RevMed, and LabGenius Therapeutics; and other consulting\/advisory role\/continuing medical education from Helsinn Healthcare, Jazz Pharmaceuticals, Incyte, Loxo Oncology\/Lilly, Novartis, Relay Therapeutics, Daiichi Sankyo, Illumina, Bayer, Medscape, OncLive, Clinical Care Communications, Physicians' Education Resource, and Med Learning Group. Balazs H reports research grants (paid to institution) from Boehringer Ingelheim, Astra Zeneca, Merck, BMS, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GSK, Beigene, Janssen, Black Diamond Therapeutics, Forward Pharma, Numab, and Arrivent; consulting for Astra Zeneca, Boehringer Ingelheim, Apollomics, Johnson & Johnson, Takeda, Merck, BMS, Genentech, Pfizer, Eli-Lilly, Daiichi, GSK; and data safety monitoring board participation with BMS, TPT, Apollomics, eFECTOR, City of Hope, and Nuvalent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study was conducted in accordance with guidelines of the Declaration of Helsinki, Belmont report, and U.S. Common rule. As this study was performed utilizing retrospective, de-identified clinical data, it is considered IRB exempt per 45 CFR 46.104(d)(4). A waiver of patient informed consent was also granted due to the retrospective, de-identified nature of the data. Waiver of patient consent and exempt status were determined by WCG IRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"165"}}